• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    EyePoint, Inc. - Common Stock (NQ:EYPT)

    4.690 -10.060 (-68.20%)
    Streaming Delayed Price Updated: 1:19 PM EDT, Aug 17, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 36,451,808
    Open 4.060
    Bid (Size) 4.680 (13,000)
    Ask (Size) 4.690 (9,300)
    Prev. Close 14.75
    Today's Range 3.950 - 4.700
    52wk Range 9.650 - 19.11
    Shares Outstanding 34,984,044
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
    Via Chartmill
    News headline image
    EyePoint’s DURAVYU Misses Primary Endpoint in Phase III Wet AMD Trial ↗
    Eyepoint Pharmaceuticals (NASDAQ:EYPT) reported topline results from LUGANO, the first of two Phase III trials evaluating DURAVYU, a vorolanib intravitreal insert, in patients with wet age-related... 
    Via MarketBeat

    Performance

    YTD
    -73.2%
    -73.2%
    1 Month
    -64.7%
    -64.7%
    3 Month
    -59.9%
    -59.9%
    6 Month
    -68.5%
    -68.5%
    1 Year
    -58.6%
    -58.6%

    More News

    Read More
    There are notable gap-ups and gap-downs in today's session. ↗
    Via Chartmill
    These stocks are moving in today's pre-market session ↗
    Via Chartmill
    EyePoint (NASDAQ:EYPT) Rallies Despite Wider Q2 Loss as Phase 3 Data Nears ↗
    Via Chartmill
    EyePoint Inc. (NASDAQ:EYPT) Revenue Beats Estimates, Earnings Miss in Q1 2026 Report ↗
    Via Chartmill
    Topics Earnings
    EyePoint Inc (NASDAQ:EYPT) Stock Falls on Q4 Earnings and Revenue Miss ↗
    Via Chartmill
    News headline image
    Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could ↗
    Via The Motley Fool
    News headline image
    EyePoint Pharmaceuticals Eyes Transformative 2026 as DURAVYU Phase 3 Data Nears ↗
    Via MarketBeat
    News headline image
    Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally ↗
    Via The Motley Fool
    News headline image
    Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    EyePoint (EYPT) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment ↗
    Via The Motley Fool
    News headline image
    EyePoint (EYPT) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Retina’s ‘Sustained’ Moment: Ocular Therapeutix Braces for Game-Changing Phase 3 AXPAXLI Data
    Via MarketMinute
    News headline image
    The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market
    Via MarketMinute
    Topics Artificial Intelligence ETFs Initial Public Offering
    News headline image
    Small-Cap Renaissance: Russell 2000 Scales New Heights While Big Tech Stumbles
    Via MarketMinute
    Topics Artificial Intelligence Economy Intellectual Property
    News headline image
    The Great Rotation: Small Caps Lead the Charge as 2026 Trading Opens
    Via MarketMinute
    Topics Artificial Intelligence ETFs Economy
    News headline image
    The Small-Cap Renaissance: Why 2026 is the Year of the Russell 2000 and XSU
    Via MarketMinute
    Topics Artificial Intelligence ETFs Economy
    News headline image
    The 2026 Horizon: Technical Breakouts Signal a Sustained Bull Run in AI and Energy
    Via MarketMinute
    Topics Artificial Intelligence Economy Intellectual Property

    Frequently Asked Questions

    Is EyePoint, Inc. - Common Stock publicly traded?
    Yes, EyePoint, Inc. - Common Stock is publicly traded.
    What exchange does EyePoint, Inc. - Common Stock trade on?
    EyePoint, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for EyePoint, Inc. - Common Stock?
    The ticker symbol for EyePoint, Inc. - Common Stock is EYPT on the Nasdaq Stock Market
    What is the current price of EyePoint, Inc. - Common Stock?
    The current price of EyePoint, Inc. - Common Stock is 4.690
    When was EyePoint, Inc. - Common Stock last traded?
    The last trade of EyePoint, Inc. - Common Stock was at 08/17/26 01:19 PM ET
    What is the market capitalization of EyePoint, Inc. - Common Stock?
    The market capitalization of EyePoint, Inc. - Common Stock is 164.08M
    How many shares of EyePoint, Inc. - Common Stock are outstanding?
    EyePoint, Inc. - Common Stock has 164M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.